Introduction {#sec1}
============

The 2-aminopyridine derivatives (APDs) are one of the most important classes of N-containing heterocycles, which are also ubiquitous structural motifs in natural or synthetic biologically active molecules or drugs. This kind of compounds usually have broad spectrum biological activity, including anti-HIV,^[@ref1]^ antitumor^[@ref2]−[@ref9]^ ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}; Crizotinib^[@ref2],[@ref3]^ and Asciminib^[@ref4]^), anti-inflammatory,^[@ref10]^ antifungal,^[@ref11]^ antihistamine,^[@ref12],[@ref13]^ antidepressant, antiarthritic, santidiabetic, antiglaucoma,^[@ref14]^ and antiprion ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref15]^ These derivatives are widely used as inhibitors of a variety of proteins, such as activin A receptor type 1 (ACVR1),^[@ref16]^ nitric oxide synthase 1 (NOS1),^[@ref17],[@ref18]^ A~2A~ adenosine receptor (ADORA2A) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}),^[@ref19]^ and so forth.^[@ref20]^ Consequently, various methods for the synthesis of 2-aminopyridines have been developed.^[@ref21]−[@ref27]^ The classic methods include the nucleophilic substitution reaction (SN) of 2-bromopyridines ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}a),^[@ref21],[@ref22]^ ruthenium-catalyzed cyclization reaction ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}b),^[@ref23]^ nucleophilic reagents reaction with in situ generated 1,4-oxazepines from N-propargylic β-enaminones followed by spontaneous N-deformylation to APDs ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}c),^[@ref24],[@ref25]^ and ruthenium-mediated \[2 + 2 + 2\] cycloaddition of α,ω-diynes and cyanamides ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}d).^[@ref26]^ Although these methods have been very valuable in the synthesis of APDs, they generally have some shortcomings, including the complexity of the structure of the substrates for the synthesis of APDs requires multistep and hazardous processes for its construction, the approach often requires harsh conditions such as the use of a metal-catalyst, and the yield and atom economy do not meet the demands of medical and biological research.

![Bioactive 2-aminopyridines, indenopyridines, and the target compounds **6**--**8**.](ao-2018-03284z_0001){#fig1}

![Methods for the Synthesis of APDs](ao-2018-03284z_0003){#sch1}

In addition, indanone derivatives are considerably important because of their interesting biological activities.^[@ref28]−[@ref30]^ Among them, indenopyridine derivatives are an important class of pharmaceuticals and bioactive natural products as a result of their significant and wide-spectrum biological activities and are widely used as antitumor or antiproliferative drugs,^[@ref28],[@ref29]^ antimalarial agents, and ADORA2A antagonist agents ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref19]^ Although there are some methods for the synthesis of these molecules,^[@ref28]−[@ref32]^ these methods require multistep synthesis and strict anhydrous conditions. Thus, there is a need for the development of concise and effective methods for preparing the target compound library.

The 1,1-enediamines (EDAMs) are a variety of building blocks that are usually used as bis-nucleophiles (α-carbon and N as nucleophilic sites) to react with bis-electrophiles and produce heterocyclic compounds, including pyridin-2-ones, pyrimidin-4-ones, imidazopyridinium derivatives, and morphan derivatives.^[@ref33]−[@ref40]^ As part of our ongoing research effort, we used EDAMs as a substrate to react with dimethylformamide dimethyl acetal (DMF-DMA) **2** and 1,3-dicarbonyl compounds **3** for the synthesis of 2-aminopyridines **6** ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). Notably, the reaction for synthesis of the target compounds **6** is completely different from the reported reaction. In this study, the C(1) of EDAMs **1** serves to attack the electrophilic sites C(1) of 1,3-dicarbonyl compounds **3** maybe as a result of the high eletrophilicity of the C(1) of substrate **3** and the little steric effects of the R′ group of compound **3**. In addition, on the basis of the splicing principle of the molecular structure of the drug, we combined the two active core structures (cyclohexanone/indanone and 2-aminopyridine) in the target compounds with the aim of producing a new class of pharmaceutical molecule which may possess potential biological activities. Accordingly, the cyclohexanone-fused APDs **7** and the indenopyridine derivatives **8** were easily prepared by this method. Here, the N(2) of EDAMs **1** serves to attack the electrophilic sites C(1) of 1,3-dicarbonyl compounds **4/5** maybe as a result of the low eletrophilicity of the C(1) of substrate **4/5** and the steric effects of the R′ group of compound **4/5** ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). Therefore, we can successfully regioselectively synthesize three kinds of 2-aminopyridines based on the structural difference of the substrates **3--5** ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). This approach provides the key information to design new substrates to react with EDAMs to synthesize various 2-aminopyridines, 2-aminoquinolones, 2-aminopyrroles, 2-aminoindoles, and so forth, via one-pot multicomponent reactions rather than multistep synthesis.

Results and Discussion {#sec2}
======================

To find the optimal reaction conditions for the synthesis of our target molecule, the reaction of (*Z*)-*N*-(4-methylphenethyl)-2-nitroethene-1,1-diamine **1b**, DMF-DMA **2** and ethyl 3-oxobutanoate (**3a**) was chosen as the model reaction. First, the three-component reaction was performed in different solvents, which included acetone, ethanol, acetonitrile, and 1,4-dioxane, at reflux conditions ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 1--4). The results showed that the reaction could not proceed at all. Then, Cs~2~CO~3~ was added to the mixture as a promoter in the above-mentioned solvents at the reflux temperature ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 5--8). The results revealed that the reaction promoted by Cs~2~CO~3~ still could not proceed in acetone, ethanol, or acetonitrile ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 5--7). Fortunately, however, when 1,4-dioxane was used as the solvent under the same conditions, the reaction produced the target compound with an excellent yield (88%) ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 8). The use of another inorganic base, namely, K~2~CO~3,~ as promoter with acetonitrile or 1,4-dioxane as solvent and at reflux conditions, revealed that only when using 1,4-dioxane the reactions proceed smoothly and can produce the target compound in good yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 10). On the basis of these results, the stronger organic base potassium tert-butoxide (*t*-BuOK) was separately added to acetone, ethanol, acetonitrile or 1,4-dioxane at reflux conditions for 12 h ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 11--14). The results indicated that positive results can only be obtained with 1,4-dioxane ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 14). On the basis of the above findings, we concluded that 1,4-dioxane is the optimal solvent for this reaction. We also compared yields obtained with the three promoters K~2~CO~3~, Cs~2~CO~3~, and *t*-BuOK and found that the best promoter is Cs~2~CO~3~ ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 8 vs 10 &14). Next, the reaction times were evaluated ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 8 vs 15). We found that the best reaction time was about 5 h. Finally, we additionally examined the effects of the amount of promoter on the reaction yields. When the amount of catalyst Cs~2~CO~3~ was adjusted to 10% (0.01 mmol) of the amount of substrate **1b**, the reaction produced the target compound **6a** with a 90% yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 16 vs 15). Accordingly, we assumed that 0.05 equiv Cs~2~CO~3~ was sufficient for this reaction.

###### Optimization of the Reaction Condition[a](#t1fn1){ref-type="table-fn"}

![](ao-2018-03284z_0006){#GRAPHIC-d7e548-autogenerated}

  entry   solvent        catalyst                                     *T* (°C)   *t* (h)   yield[b](#t1fn2){ref-type="table-fn"} (%)
  ------- -------------- -------------------------------------------- ---------- --------- -------------------------------------------
  1       acetone                                                     reflux     12        n.r
  2       EtOH                                                        reflux     12        n.r
  3       acetonitrile                                                reflux     12        n.r
  4       1,4-dioxane                                                 reflux     12        n.r
  5       acetone        Cs~2~CO~3~[c](#t1fn3){ref-type="table-fn"}   reflux     12        n.r
  6       EtOH           Cs~2~CO~3~[c](#t1fn3){ref-type="table-fn"}   reflux     12        n.r
  7       acetonitrile   Cs~2~CO~3~[c](#t1fn3){ref-type="table-fn"}   reflux     12        n.r
  8       1,4-dioxane    Cs~2~CO~3~[c](#t1fn3){ref-type="table-fn"}   reflux     12        88
  9       acetonitrile   K~2~CO~3~[c](#t1fn3){ref-type="table-fn"}    reflux     12        n.r
  10      1,4-dioxane    K~2~CO~3~[c](#t1fn3){ref-type="table-fn"}    reflux     12        85
  11      acetone        *t*-BuOk[c](#t1fn3){ref-type="table-fn"}     reflux     12        n.r
  12      EtOH           *t*-BuOk[c](#t1fn3){ref-type="table-fn"}     reflux     12        n.r
  13      acetonitrile   *t*-BuOk[c](#t1fn3){ref-type="table-fn"}     reflux     12        n.r
  14      1,4-dioxane    *t*-BuOk[c](#t1fn3){ref-type="table-fn"}     reflux     12        86
  15      1,4-dioxane    Cs~2~CO~3~[c](#t1fn3){ref-type="table-fn"}   reflux     5         91
  16      1,4-dioxane    Cs~2~CO~3~[d](#t1fn4){ref-type="table-fn"}   reflux     5         90

Reaction conditions: EDAM **1b** (1.0 mmol), DMF-DMA **2** (1.5 mmol), **3a** (1.0 mmol) and solvent (8 mL).

Isolated yield based on **1b**.

Catalyst (0.05 mmol).

Catalyst (0.1 mmol).

With the optimal conditions in hand, we explored the scope and limitations of the three-component cascade reaction with various EDAMs and a variety of 1,3-dicarbonyl compounds. The results revealed that in all cases the reaction proceeded smoothly in 1,4-dioxane at reflux conditions for about 5 h ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, entries 1--16). The different substituent groups (R) of the EDAMs **1** usually had a slight effect on the yields, but the difference is very small, and we cannot ascertain the effect of any specific substituent. However, the substituent group of 1,3-dicarbonyl compounds **3** has an obvious effect on the yield of compounds **6**. In general, the substrates **3a** and **3b** are usually more favorable to the yield of the target compounds than the substrates **3c**--**3e**. Overall, the different substituted substrates **1** and **3** easily reacted with DMF-DMA **2** to produce compound **6** with good to excellent yields (74--92%).

###### Synthesis of 2-Aminopyridines 6[a](#t2fn1){ref-type="table-fn"}

![](ao-2018-03284z_0007){#GRAPHIC-d7e1038-autogenerated}

  entry   R                              R′      R″                **1**    **3**    **6**    yield[b](#t2fn2){ref-type="table-fn"} (%)
  ------- ------------------------------ ------- ----------------- -------- -------- -------- -------------------------------------------
  1       *p*-CH~3~C~6~H~4~CH~2~CH~2~    CH~3~   OCH~2~CH~3~       **1b**   **3a**   **6a**   91
  2       C~6~H~5~CH~2~CH~2~             CH~3~   OCH~2~CH~3~       **1c**   **3a**   **6b**   91
  3       *m*-FC~6~H~4~CH~2~CH~2~        CH~3~   OCH~2~CH~**3**~   **1d**   **3a**   **6c**   92
  4       *p*-ClC~6~H~4~CH~2~            CH~3~   OCH~2~CH~3~       **1f**   **3a**   **6d**   91
  5       *p*-FC~6~H~4~CH~2~             CH~3~   OCH~2~CH~3~       **1g**   **3a**   **6e**   91
  6       *p*-CH~3~OC~6~H~4~CH~2~CH~2~   CH~3~   CH~3~             **1a**   **3b**   **6f**   89
  7       *p*-CH~3~C~6~H~4~CH~2~CH~2~    CH~3~   CH~3~             **1b**   **3b**   **6g**   92
  8       C~6~H~5~CH~2~CH~2~             CH~3~   CH~3~             **1c**   **3b**   **6h**   91
  9       *m*-FC~6~H~4~CH~2~CH~2~        CH~3~   CH~3~             **1d**   **3b**   **6i**   92
  10      *o*-FC~6~H~4~CH~2~CH~2~        CH~3~   CH~3~             **1e**   **3b**   **6j**   91
  11      *p*-ClC~6~H~4~CH~2~            CH~3~   CH~3~             **1f**   **3b**   **6k**   90
  12      *p*-CH~3~C~6~H~4~CH~2~CH~2~    CF~3~   CF~3~             **1b**   **3c**   **6l**   87
  13      *m*-FC~6~H~4~CH~2~CH~2~        CF~3~   CF~3~             **1e**   **3c**   **6m**   85
  14      *p*-ClC~6~H~4~CH~2~            CF~3~   Ph                **1f**   **3d**   **6n**   84
  15      C~6~H~5~CH~2~CH~2~             Ph      Ph                **1c**   **3e**   **6o**   76
  16      *m*-FC~6~H~4~CH~2~CH~2~        Ph      Ph                **1e**   **3e**   **6p**   74

Reaction conditions: **1** (1.0 mmol), **2** (1.5 mmol), **3** (1.0 mmol), and solvent (8 mL).

Isolated yield based on **1**.

To further investigate the scope and limitations of the cascade reaction, we reacted cyclic 1,3-dicarbonyl compounds (cyclohexane-1,3-dione derivatives) with various EDAMs **1** and DMF-DMA **2**, and we find that the optimal reaction time is about 10 h. Interestingly, the reaction produced another kind of 2-aminopyridines **7** ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entries 1--14). In this reaction, the C(1) of EDAMs **1** serves to attack the electrophilic sites C(1′) of the intermediate formed from substrate **4** and DMF-DMA **2** ([Schemes [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"} and [2](#sch2){ref-type="scheme"}). Thus, different substituted EDAMs were also used as a substrate and reacted with DMF-DMA and cyclohexane-1,3-dione derivatives **4a**--**4b**, which all produced the target compounds **7** with excellent yields, except for compound **7h** ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entries 1**--**14). The substituted groups on substrates **1** and **4** had almost no effect on the yield, which indicated that various substrates can produce ideal results.

![Proposed Mechanism for the Formation of 2-Aminopyridines 6](ao-2018-03284z_0004){#sch2}

###### Synthesis of APDs 7[a](#t3fn1){ref-type="table-fn"}

![](ao-2018-03284z_0008){#GRAPHIC-d7e1909-autogenerated}

  entry   R                              R′      **1**    **4**    **7**    yield[b](#t3fn2){ref-type="table-fn"} (%)
  ------- ------------------------------ ------- -------- -------- -------- -------------------------------------------
  1       *p*-CH~3~OC~6~H~4~CH~2~CH~2~   CH~3~   **1a**   **4a**   **7a**   90
  2       *p*-CH~3~C~6~H~4~CH~2~CH~2~    CH~3~   **1b**   **4a**   **7b**   92
  3       C~6~H~5~CH~2~CH~2~             CH~3~   **1c**   **4a**   **7c**   92
  4       *m*-FC~6~H~4~CH~2~CH~2~        CH~3~   **1d**   **4a**   **7d**   90
  5       *o*-FC~6~H~4~CH~2~CH~2~        CH~3~   **1e**   **4a**   **7e**   90
  6       *p*-ClC~6~H~4~CH~2~            CH~3~   **1f**   **4a**   **7f**   90
  7       *p*-FC~6~H~4~CH~2~             CH~3~   **1g**   **4a**   **7g**   91
  8       C~6~H~5~                       CH~3~   **1h**   **4a**   **7h**   76
  9       *p*-CH~3~OC~6~H~4~CH~2~CH~2~   H       **1a**   **4b**   **7i**   90
  10      *p*-CH~3~C~6~H~4~CH~2~CH~2~    H       **1b**   **4b**   **7j**   92
  11      C~6~H~5~CH~2~CH~2~             H       **1c**   **4b**   **7k**   91
  12      *m*-FC~6~H~4~CH~2~CH~2~        H       **1d**   **4b**   **7l**   90
  13      *o*-FC~6~H~4~CH~2~CH~2~        H       **1e**   **4b**   **7m**   91
  14      *p*-ClC~6~H~4~CH~2~            H       **1f**   **4b**   **7n**   91

Reagents and conditions: **1** (1.0 mmol), **2** (1.5 mmol), **4** (1.0 mmol) and solvent (8 mL).

Isolated yield based on **1**.

On the basis of above results, we examined the scope and limitations of the cascade reaction using the cyclic 1,3-dicarbonyl compound 1*H*-indene-1,3(2*H*)-dione ([Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}, entries 1--8). The results showed that the different substituent groups of EDAMs **1** usually had a slight effect on the yields. As a result, we can obtain the target compounds **8** with excellent yields ([Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}, entries 1--8).

###### Synthesis of APDs 8[a](#t4fn1){ref-type="table-fn"}

![](ao-2018-03284z_0009){#GRAPHIC-d7e2552-autogenerated}

  entry   R                              **1**    **8**    yield[b](#t4fn2){ref-type="table-fn"} (%)
  ------- ------------------------------ -------- -------- -------------------------------------------
  1       *p*-CH~3~OC~6~H~4~CH~2~CH~2~   **1a**   **8a**   89
  2       *p*-CH~3~C~6~H~4~CH~2~CH~2~    **1b**   **8b**   93
  3       C~6~H~5~CH~2~CH~2~             **1c**   **8c**   91
  4       *m*-FC~6~H~4~CH~2~CH~2~        **1d**   **8d**   91
  5       *o*-FC~6~H~4~CH~2~CH~2~        **1e**   **8e**   92
  6       *p*-ClC~6~H~4~CH~2~            **1f**   **8f**   92
  7       C~6~H~5~                       **1g**   **8g**   90
  8       CH~3~                          **1h**   **8h**   86

Reagents and conditions: **1** (1.0 mmol), **2** (1.5 mmol), **5** (1.0 mmol), and solvent (8 mL).

Isolated yield based on **1**.

The chemical structure of all target derivatives (**6**--**8**) was fully characterized by infrared (IR) spectroscopy, proton (^1^H) nuclear magnetic resonance (NMR), carbon-13 (^13^C) NMR and high-resolution mass spectrometry (HRMS). To further verify the structure of the target products, some of the representative compounds (**6g**, **7f**, and **8b**) were separately selected as representative compounds, whose presence was unequivocally confirmed by X-ray diffraction analysis as shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} (CCDC1879680, CCDC1879681, and CCDC1879683).

![X-ray crystal structures of **6g**, **7f**, and **8b**; ellipsoids are drawn at the 30% probability level.](ao-2018-03284z_0002){#fig2}

On the basis of the above experimental results, we propose the mechanism for the formation of the target compounds **6** as outlined in [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}. First, DMF-DMA **2** reacts with 1,3-dicarbonyl compounds **3** to form compounds **9**. Next, the α-C of EDAMs **1** serves as the nucleophilic site to attack the carbonyl of compounds **9** through 1,2-addition reaction promoted by the base to produce the intermediates **10**. This was followed by the imine-enamine tautomerization to obtain the intermediates **10**. Then, intermediates **10** undergo imine-enamine tautomerization and produce the intermediates **11**. Afterward, the amino group of intermediates **11** attacks the C=C bond of the intermediates **11** via Michael addition following the loss of one molecule of NH(Me)~2~ to produce the intermediates **12** promoted by the base. Finally, the intermediate **12** undergoes aromatization and loses one molecule of H~2~O promoted by heat to give the target compounds **6** ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}).

However, the proposed mechanism for the formation of the target compounds **7**--**8** is different from that of compounds **6**. Thus, in this work, we also proposed the mechanism for the formation of the target compounds **7** ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}), as follows. Initially, DMF-DMA **2** is reacted with cyclic 1,3-dicarbonyl compounds **5** to form compounds **13**. Next, the α-C of EDAMs **1** serves as the nucleophilic site to attack the C=C bond of compounds **13** through the Michael addition reaction followed by the loss of one molecule of NH(Me)~2~ promoted by the base to produce the intermediates **14**. Then, the intermediates **14** produce the intermediate **15** via imine-enamine tautomerization promoted by the base. Afterward, the intermediates **15** produce intermediates **16** through an intramolecular cyclization reaction. Eventually, the intermediate **16** undergoes aromatization and, promoted by heat, loses one molecule of H~2~O to give the target compounds **7** ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}).

![Proposed Mechanism for the Formation of APDs 7](ao-2018-03284z_0005){#sch3}

Conclusions {#sec3}
===========

In summary, we have developed a concise method for the regioselective synthesis of novel APDs via a base-promoted three-component cascade reaction of EDAMs **1**, DMF-DMA **2**, and 1,3-dicarbonyl compounds **3**--**5**. This method has some advantages, such as low-cost, simple operation without step by step isolation and purification, high yields, the diversity of the target compounds, readily accessible building blocks and potential biological activity of the product. Moreover, we found two different mechanisms of the reaction and compared the substrate **3** with **4--5**. This is very interesting because the mechanism of formation of the target compound **6** is based on substrate **3**. This protocol provides a useful strategy to construct various kinds of 2-aminoheterocycles including 2-aminopyridines, 2-aminopyrroles, 2-aminoquinolines, 2-aminoindoles, and others in the future.

Experimental Section {#sec4}
====================

General Methods {#sec4.1}
---------------

All compounds were fully characterized by spectroscopic data. The NMR spectra were recorded on a Bruker DRX500 & DRX600. Chemical shifts (δ) are expressed in ppm, *J* values are given in Hz, and deuterated DMSO-*d*~6~ & CDCl~3~ were used as the solvent. IR spectra were recorded on a FT-IR Thermo Nicolet Avatar 360 using a KBr pellet. The reactions were monitored by thin layer chromatography using silica gel GF~254~. The melting points were determined on a XT-4A melting point apparatus and are uncorrected. HRMs were performed on an Agilent LC/Msd TOF instrument.

Materials used were purchased from Adamas-beta Corporation Limited. All chemicals and solvents were used as received without further purification unless otherwise noted. Column chromatography was performed on silica gel (200--300 mesh). EDAMs **1** were prepared according to the literature.^[@ref41],[@ref42]^

General Procedure for the Synthesis of Compounds 6--8 {#sec4.2}
-----------------------------------------------------

A 25 mL round bottom flask was charged with 1,3-dicarbonyl compounds **3**--**5** (1.0 mmol), 1,4-dioxane (8 mL), and DMF-DMA **2** (1.5 mmol). The mixture was reflux for about 0.5 h. Next, EDAMs **1** (1.0 mmol) and a small amount of Cs~2~CO~3~ (0.05 mmol) were added to this mixture, and the solution was stirred for about 5--10 h at reflux. Then, the mixture was cooled to room temperature and added to 50 mL of water, followed by extraction with an appropriate amount of ethyl acetate. The organic phase was combined and dried over anhydrous Na~2~SO~4~ and then concentrated under reduced pressure and purified by fast column chromatography (with the appropriate proportion of petroleum ether and ethyl acetate). Eventually, the target compounds **6**--**8** were obtained with yields of 74--93%.

### Ethyl 4-methyl-6-((4-methylphenethyl)amino)-5-nitronicotinate (**6a**) {#sec4.2.1}

Yellow solid; mp 74.0 °C; IR (KBr): 3417, 2956, 1602, 1562, 1360, 1293 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.30 (t, *J* = 7.0 Hz, 3H, CH~3~), 2.26 (s, 3H, ArCH~3~), 2.51 (s, 3H, CH~3~), 2.79--2.81 (m, 2H, CH~2~), 3.60--3.64 (m, 2H, NCH~2~), 4.24--4.28 (m, 2H, OCH~2~), 7.07--7.11 (m, 4H, ArH), 7.68 (s, 1H, CH), 8.70 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 14.5, 15.8, 21.1, 43.6, 34.7, 61.0, 114.0, 129.0, 129.3, 134.1, 135.5, 136.6, 142.7, 151.4, 153.4, 165.2. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~18~H~22~N~3~O~3~, 344.1605; found, 344.1604.

### Ethyl 4-methyl-5-nitro-6-(phenethylamino)nicotinate (**6b**) {#sec4.2.2}

Yellow solid; mp 75.0 °C; IR (KBr): 3454, 2959, 1605, 1555, 1386, 1261 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.31 (t, *J* = 7.0 Hz, 3H, CH~3~), 2.41 (s, 3H, CH~3~), 2.84--2.87 (m, 2H, CH~2~), 3.63--3.67 (m, 2H, NCH~2~), 4.24--4.28 (m, 2H, OCH~2~), 7.18--7.22 (m, 3H, ArH), 7.27--7.30 (m, 2H, ArH), 7.70 (s, 1H, CH) 8.70 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 14.5, 15.8, 35.1, 42.8, 61.0, 114.1, 126.6, 128.8, 129.1, 134.2, 139.7, 142.7, 151.4, 153.4, 165.2. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~17~H~20~N~3~O~4~, 330.1448; found, 330.1449.

### Ethyl 6-((3-fluorophenethyl)amino)-4-methyl-5-nitronicotinate (**6c**) {#sec4.2.3}

Yellow solid; mp 77.0 °C; IR (KBr): 3432, 1708, 1602, 1555, 935, 895 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.30 (t, *J* = 7.0 Hz, 3H, CH~3~), 2.40 (s, 3H, CH~3~), 2.87--2.90 (m, 2H, CH~2~), 3.65--3.69 (m, 2H, NCH~2~), 4.24--4.28 (m, 2H, OCH~2~), 7.01--7.05 (m, 3H, Ar), 7.30--7.33 (m, 1H, Ar), 7.68 (s, 1H, CH), 8.69 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 14.5, 15.8, 34.7, 42.4, 61.0, 113.3 (d, *J* = 20.0 Hz), 114.1, 115.8 (d, *J* = 20.0 Hz), 125.3 (d, *J* = 2.5 Hz), 130.6 (d, *J* = 7.5 Hz), 134.2, 142.7 (d, *J* = 15.0 Hz), 151.3, 153.3, 161.7, 163.6, 165.2. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~17~H~19~FN~3~O~4~, 348.1354; found, 348.1352.

### Ethyl 6-((4-chlorobenzyl)amino)-4-methyl-5-nitronicotinate (**6d**) {#sec4.2.4}

Yellow solid; mp 89 °C; IR (KBr): 3409, 1716, 1601, 1519, 1017, 796 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.26 (t, *J* = 7.0 Hz, 3H, CH~3~), 2.4 (s, 3H, CH~3~), 4.22--4.27 (m, 2H, OCH~2~), 4.61--4.62 (d, *J* = 6.0 Hz, 2H, CH~2~), 7.29--7.31 (m, 2H, ArH), 7.35--7.37 (m, 2H, ArH), 8.23 (s, 1H, CH), 863 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 14.5, 15.8, 43.8, 61.0, 114.7, 128.7, 129.5, 131.8, 134.3, 138.8, 142.7, 151.2, 153.2, 165.1. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~16~H~17~ClN~3~O~43~, 350.0902; found, 350.0899.

### Ethyl 6-((4-fluorobenzyl)amino)-4-methyl-5-nitronicotinate (**6e**) {#sec4.2.5}

Yellow solid; mp 111.0 °C; IR (KBr): 3410, 1715, 1651, 1607, 1044, 876 cm^--1^; ^19^F NMR (470 MHz, DMSO-*d*~6~): δ −116.2; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.29 (t, *J* = 7.0 Hz, 3H, CH~2~CH~3~), 2.41 (s, 3H, COCH~3~), 4.22--4.27 (m, 2H, OCH~2~), 4.61--4.62 (m, 2H, CH~2~), 7.11--7.14 (m, 2H, ArH), 7.31--7.34 (m, 2H, ArH), 8.22 (s, 1H, CH), 8.65 (br, 1H, NH); (d, *J* = 240 Hz), 165.1; ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 14.5, 15.8, 43.7, 61.0, 114.6, 115.4 (d, *J* = 21.3 Hz), 129.6 (d, *J* = 8.8 Hz), 143.3, 135.9 (d, *J* = 2.5 Hz), 142.7, 151.2, 153.2, 161.6 (d, *J* = 240.0 Hz), 165.1. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~16~H~17~FN~3~O~43~, 334.1198; found, 334.1195.

### 1-(6-((4-Methoxyphenethyl)amino)-4-methyl-5-nitropyridin-3-yl)ethanone (**6f**) {#sec4.2.6}

Yellow solid; mp 105.0 °C; IR (KBr): 3339, 1658, 1600, 1525, 1021, 820 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.34 (s, 3H, COCH~3~), 2.50--2.54 (m, 3H, CH~3~), 2.78--2.80 (m, 2H, CH~2~), 3.60--3.64 (m, 2H, NCH~2~), 3.72 (s, 3H, OCH~3~), 6.84--6.87 (m, 2H, ArH), 7.12--7.14 (m, 2H, ArH), 7.68 (s, 1H, CH), 8.82 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 15.9, 29.6, 34.3, 43.1, 55.5, 114.3, 121.7, 130.1, 131.6, 134.9, 141.5, 150.8, 154.0, 158.2, 197.4. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~17~H~20~N~3~O~4~, 330.1448; found, 330.1446.

### 1-(4-Methyl-6-((4-methylphenethyl)amino)-5-nitropyridin-3-yl)ethanone (**6g**) {#sec4.2.7}

Yellow solid; mp 115.5 °C; IR (KBr): 3402, 1671, 1598, 1551, 960, 878 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 2.33 (S, 3H, ArCH~3~), 2.55 (s, 3H, CH~3~), 2.56 (s, 3H, COCH~3~), 2.89--2.91 (m, 2H, CH~2~), 3.77--3.81 (m, 2H, NCH~2~), 6.53 (s, 1H, CH), 7.10--7.12 (m, 4H, ArH), 8.69 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ 17.0, 21.0, 29.3, 35.0, 43.0, 123.4, 128.6, 129.4, 133.6, 135.4, 136.3, 145.4, 151.7, 153.5, 196.9. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~17~H~20~N~3~O~3~, 314.1499; found, 314.1496.

### 1-(4-Methyl-5-nitro-6-(phenethylamino)pyridin-3-yl)ethanone (**6h**) {#sec4.2.8}

Yellow solid; mp 66 °C; IR (KBr): 3373, 1674, 1665, 1593, 942, 875 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.34 (s, 3H, CH~3~), 2.50--2.54 (m, 3H, COCH~3~), 2.85--2.88 (m, 2H, CH~2~), 3.64--3.68 (m, 2H, NCH~2~), 7.19--7.23 (m, 3H, ArH), 7.28--7.31 (m, 2H, ArH), 7.70 (s, 1H, CH), 8.82 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 15.9, 29.6, 35.2, 42.8, 121.9, 126.6, 129.0, 129.1, 134.9, 139.8, 141.5, 150.8, 153.9, 197.4. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~16~H~18~N~3~O~3~, 300.1343; found, 300.1341.

### 1-(6-((3-Fluorophenethyl)amino)-4-methyl-5-nitropyridin-3-yl)ethanone (**6i**) {#sec4.2.9}

Yellow solid; mp 79.5 °C; IR (KBr): 3411, 1671, 1598, 1551, 960, 878 cm^--1^; ^1^H NMR (600 MHz, CDCl~3~):δ 2.55 (s, 3H, CH~3~), 2.57 (s, 3H, COCH~3~), 2.93--2.96 (m, 2H, CH~2~), 3.81--3.84 (m, 2H, NCH~2~), 6.62--6.67 (m, 1H, ArH), 6.93--6.95 (m, 2H, ArH), 6.99--7.00 (m, 1H, ArH), 7.27 (s, 1H, CH), 8.70 (br, 1H, NH); ^13^C NMR (150 MHz, CDCl~3~): δ 17.0, 29.3, 35.2, 42.6, 113.6 (d, *J* = 21.0 Hz), 115.6 (d, *J* = 21.0 Hz), 123.6, 124.4 (d, *J* = 3.0 Hz), 130.2 (d, *J* = 9.0 Hz), 133.7, 141.1 (d, *J* = 7.5 Hz), 145.4, 151.6, 153.4, 160.3 (d, *J* = 244.5 Hz), 196.9. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~16~H~17~FN~3~O~3~, 318.1248; found, 318.1246.

### 1-(6-((2-Fluorophenethyl)amino)-4-methyl-5-nitropyridin-3-yl)ethanone (**6j**) {#sec4.2.10}

Yellow solid; mp 89.0 °C; IR (KBr): 3410, 1673, 1604, 1525, 949, 830 cm^--1^; ^19^F NMR (470 MHz, DMSO-*d*~6~): δ −118.7; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.33 (s, 3H, COCH~3~), 2.51--2.53 (m, 3H, CH~3~), 2.90--2.92 (m, 2H, CH~2~), 3.67--3.68 (m, 2H, NCH~2~), 7.12--7.14 (m, 2H, ArH), 7.25--7.27 (m, 2H, ArH), 7.73 (s, 1H, CH), 8.80 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 15.9, 115.5 (d, *J* = 22.5 Hz), 121.9, 124.8 (d, *J* = 3.8 Hz), 126.3 (d, *J* = 16.0 Hz), 128.8 (d, *J* = 8.9 Hz), 131.8 (d, *J* = 3.8 Hz), 134.9, 141.4, 150.8, 153.8, 160.3, 162.2, 197.5. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~16~H~17~FN~3~O~3~, 318.1248; found, 318.1245.

### 1-(6-((4-Chlorobenzyl)amino)-4-methyl-5-nitropyridin-3-yl)ethanone (**6k**) {#sec4.2.11}

Yellow solid; mp 148.0 °C; IR (KBr): 3314, 1656, 1600, 1524, 1015, 816 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.35 (s, 3H, COCH~3~), 2.51 (s, 3H, CH~3~), 4.62--4.64 (m, 2H, CH2), 7.30--7.32 (m, 2H, ArH), 7.36--7.38 (m, 2H, ArH), 8.24 (s, 1H, CH), 875 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 15.9, 29.6, 43.7, 12.3, 128.7, 129.3, 131.8, 135.0, 138.9, 141.5, 150.6, 153.7, 197.5. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~15~H~15~ClN~3~O~3~, 320.0796; found, 320.0796.

### 1-(6-((4-Methylphenethyl)amino)-5-nitro-4-(trifluoromethyl)pyridin-3-yl)ethanone (**6l**) {#sec4.2.12}

Yellow solid; mp 80.0 °C; IR (KBr): 3440, 1617, 1582, 1516, 943, 869 cm^--1^; ^19^F NMR (470 MHz, DMSO-*d*~6~): δ −68.1, −61.4; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.53 (s, 3H, CH~3~), 2.79--2.82 (m, 2H, CH~2~), 3.57--3.61 (m, 2H, NCH~2~), 7.05--7.11 (m, 4H, ArH), 7.39 (s, 1H, CH), 8.16 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.6, 34.2, 43.6, 104.2, 120.6 (d, *J* = 272.5 Hz), 121.2 (d, *J* = 273.8 Hz), 124.2, 129.0, 129.4, 130.6, 132.3 (d, *J* = 35.0 Hz), 135.6, 136.3, 148.4 (d, *J* = 35.0 Hz), 150.7. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~17~H~14~F~6~N~3~O~3~, 422.0934; found, 538.2265.

### 2,2,2-Trifluoro-1-(6-((2-fluorophenethyl)amino)-5-nitro-4-(trifluoromethyl)pyridin-3-yl)ethanone (**6m**) {#sec4.2.13}

Yellow solid; mp 82.0 °C; IR (KBr): 3455, 1624, 1581, 1532, 949, 851 cm^--1^; ^19^F NMR (470 MHz, DMSO-*d*~6~): δ −61.4, −68.1, −119.0; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.53 (s, 3H, CH~3~), 2.90--2.93 (m, 2H, CH~2~), 3.64--3.68 (m, 2H, NCH~2~), 7.09--7.13 (m, 2H, ArH), 7.22--7.27 (m, 2H, ArH), 7.38 (s, 1H, CH), 8.19 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 28.1, 41.9, 104.2, 115.5 (d, *J* = 21.3 Hz), 119.0 (d, *J* = 273.8 Hz), 120.5 (d, *J* = 273.8 Hz), 123.8, 124.6 (d, *J* = 25.0 Hz), 126.0, 128.8 (d, *J* = 8.8 Hz), 130.6, 132.3 (d, *J* = 35.0 Hz), 148.4 (d, *J* = 35.0 Hz), 150.7, 160.3, 162.2. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~16~H~11~F~7~N~3~O~3~, 426.0683 found, 538.2265.

### (6-((4-Chlorobenzyl)amino)-5-nitro-4-(trifluoromethyl)pyridin-3-yl)(phenyl)methanone (**6n**) {#sec4.2.14}

Yellow solid; mp 102.0 °C; IR (KBr): 3421, 1619, 1565, 1016, 855 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 4.73--4.74 (m, 2H, NCH~2~), 7.37--7.41 (m, 4H, ArH), 7.42--7.49 (m, 3H, ArH), 7.51--7.57 (m, 1H, ArH), 8.05 (s, 1H, CH), 8.43 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 44.3 (d, *J* = 31.3 Hz), 110.3, 121.1 (d, *J* = 273.8 Hz), 127.8 (d, *J* = 23.8 Hz), 128.6 (d, *J* = 12.5 Hz), 129.4 (d, *J* = 23.4 Hz), 130.2 (d, *J* = 15.0 Hz), 131.5, 132.0, 133.6, 134.7, 138.6, 139.1, 145.9, 146.7 (d, *J* = 35.0 Hz), 150.1. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~20~H~14~ClF~3~N~3~O~3~, 436.0670; found, 436.0673.

### (5-Nitro-6-(phenethylamino)-4-phenylpyridin-3-yl)(phenyl)methanone (**6o**) {#sec4.2.15}

Yellow solid; mp 133.0 °C; IR (KBr): 3424, 1654, 1600, 1588, 982, 959 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.91--2.94 (m, 2H, CH~2~), 3.71--3.73 (m, 2H, NCH~2~), 7.11--7.13 (m, 2H, ArH), 7.22--7.24 (m, 4H, ArH), 7.26--7.27 (m, 2H, ArH), 7.29--7.31 (m, 2H, ArH), 7.35--7.38 (m, 2H, ArH), 7.49--7.53 (m, 1H, ArH), 7.58--7.60 (m, 2H, ArH), 7.75--7.76 (m, 1H, CH), 8.39 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 35.2, 43.0, 123.7, 126.6, 128.3, 128.7, 128.9, 128.9, 129.1, 129.1, 129.1, 132.1, 133.58 (d, *J* = 25.0 Hz), 137.8, 139.8, 143.7, 150.9, 151.7, 193.8. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~26~H~22~N~3~O~3~, 424.1656; found, 424.1653.

### (6-((2-Fluorophenethyl)amino)-5-nitro-4-phenylpyridin-3-yl)(phenyl)methanone (**6p**) {#sec4.2.16}

Yellow solid; mp 99.6 °C; IR (KBr): 3406, 1654, 1592, 1513, 983, 805 cm^--1^; ^19^F NMR (470 MHz, DMSO-*d*~6~): δ −118.5 Hz; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.95--2.98 (m, 2H, CH~2~), 3.72--3.76 (m, 2H, NCH~2~), 7.10--7.17 (m, 4H, ArH), 7.23--7.24 (m, 3H, ArH), 7.27--7.29 (m, 1H, ArH), 7.31--7.50 (m, 3H, ArH), 7.50--7.51 (m, 3H, ArH), 7.57--7.59 (m, 2H, ArH), 7.78 (s, 1H, CH), 8.36 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 28.7, 41.6, 115.5 (d, *J* = 21.3 Hz), 123.7, 124.8, 126.4, 127.8, 128.3, 128.8, 128.8, 129.2, 129.9, 131.2, 131.8 (d, *J* = 5.0 Hz), 133.5 (d, *J* = 18.8 Hz), 137.8, 143.6, 150.9, 151.6, 160.3, 162.2, 193.8. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~26~H~21~FN~3~O~3~, 442.1561; found, 442.1558.

### 2-((3-Methoxyphenethyl)amino)-7,7-dimethyl-3-nitro-7,8-dihydroquinolin-5(6H)-one (**7a**) {#sec4.2.17}

Yellow solid; mp 92.0 °C; IR (KBr): 3325, 1681, 1666, 1592, 1036, 818 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 1.00 (s, 6H, CCH~3~, CCH~3~), 2.48--2.51 (m, 2H, COCH~2~), 2.86--2.89 (m, 4H, CCH~2~, CH~2~), 3.71 (s, 3H, OCH~3~), 3.81--3.85 (m, 2H, NCH~2~), 6.85--6.87 (m, 2H, ArH), 7.17--7.18 (m, 2H, ArH), 8.64 (s, 1H, CH), 8.92 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ 28.3, 32.7, 34.4, 43.4, 46.6, 51.2, 55.5, 114.4, 117.2, 127.5, 130.2, 131.4, 133.8, 153.1, 158.3, 169.6, 195.1. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~20~H~24~N~3~O~4~, 370.1761; found, 370.1762.

### 7,7-Dimethyl-2-((4-methylphenethyl)amino)-3-nitro-7,8-dihydroquinolin-5(6H)-one (**7b**) {#sec4.2.18}

Yellow solid; mp 107.5 °C; IR (KBr): 3392, 1678, 1517, 958, 811 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.02 (s, 6H, CCH~3~, CCH~3~), 2.26 (s, 3H, CH~3~), 2.48--2.51 (m, 2H, COCH~2~), 2.86--2.90 (m, 4H, CH~2~, CCH~2~), 3.82--3.86 (m, 2H, NCH~2~), 7.10--7.11 (m, 1H, ArH), 7.14--7.16 (m, 2H, ArH), 8.63 (s, 1H, CH), 8.93 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.1, 28.2, 32.6, 34.8, 43.2, 46.5, 51.1, 117.1, 127.5, 129.0, 129.4, 133.7, 135.6, 136.4, 153.0, 169.5, 195.0. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~20~H~14~N~3~O~3~, 354.1812; found, 354.1810.

### 7,7-Dimethyl-3-nitro-2-(phenethylamino)-7,8-dihydroquinolin-5(6H)-one (**7c**) {#sec4.2.19}

Yellow solid; mp 172.0 °C; IR (KBr): 3392, 1679, 1600, 1525, 1070, 857 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.03 (s, 6H, CH~3~, CH~3~), 2.48--2.50 (m, 2H, COCH~2~), 2.87 (s, 2H, CCH~2~), 2.93--2.96 (m, 2H, CH~2~), 3.85--3.89 (m, 2H, NCH~2~), 7.21--7.22 (m, 1H, ArH), 7.28--7.32 (m, 3H, ArH), 8.64 (s, 1H, CH), 8.95 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 28.3, 32.7, 35.2, 43.1, 46.5, 51.2, 117.2, 126.7, 127.5, 128.9, 129.2, 133.7, 139.5, 153.0, 169.5, 195.1. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~19~H~22~N~3~O~3~, 340.1656; found, 340.1655.

### 2-((3-Fluorophenethyl)amino)-7,7-dimethyl-3-nitro-7,8-dihydroquinolin-5(6H)-one (**7d**) {#sec4.2.20}

Yellow solid; mp 165.0 °C; IR (KBr): 3395, 1679, 16 001, 1525, 941, 866 cm^--1^; ^19^F NMR (470 MHz, DMSO-*d*~6~): δ −113.6; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.02 (s, 6H, CCH~3~, CCH~3~), 2.48--2.51 (m, 2H, COCH~2~), 2.86 (s, 2H, CCH~2~), 2.96--2.99 (m, 2H, CH~2~), 3.88--3.90 (m, 2H, NCH~2~), 7.01--7.03 (m, 1H, ArH), 7.09--7.13 (m, 2H, ArH), 7.32--7.34 (m, 1H, ArH), 8.64 (s, 1H, CH), 8.95 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 28.2, 32.6, 34.9, 42.6, 46.5, 51.1, 113.5 (d, *J* = 21.3 Hz), 115.9 (d, *J* = 20 Hz), 117.2, 125.4 (d, *J* = 1.25 Hz), 127.5, 130.6 (d, *J* = 8.75 Hz), 133.7, 142.6 (d, *J* = 7.5 Hz), 153.0, 162.7(d, *J* = 241.3 Hz), 169.4, 195.1. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~19~H~21~FN~3~O~3~, 358.1561; found, 358.1563.

### 2-((2-Fluorophenethyl)amino)-7,7-dimethyl-3-nitro-7,8-dihydroquinolin-5(6H)-one (**7e**) {#sec4.2.21}

Yellow solid; mp 187.0 °C; IR (KBr): 3385, 1680, 1601, 957, 859 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.01 (s, 3H, CH~3~), 1.02 (s,3H, CH~3~), 2.47--2.51 (m, 2H, COCH~2~), 2.82--2.83 (s, 2H, CH~2~), 2.99 (s, 2H, CCH~2~), 3.88--3.90 (m, 2H, NCH~2~), 7.10--7.16 (m, 2H, ArH), 7.24--7.25 (m, 1H, ArH), 7.30--7.32 (m, 1H, ArH), 8.63 (s, 1H, CH), 9.01 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 28.3, 28.7, 32.6, 41.6, 46.4, 51.2, 115.4, 115.6, 117.2, 124.8, 126.2, 126.3, 127.5, 128.9, 131.8, 133.7, 153.1, 169.4, 195.1. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~19~H~21~FN~3~O~3~, 358.1561; found, 358.1563.

### 2-((4-Chlorobenzyl)amino)-7,7-dimethyl-3-nitro-7,8-dihydroquinolin-5(6H)-one (**7f**) {#sec4.2.22}

Yellow solid; mp 162.5 °C; IR (KBr): 3385, 1682, 1592, 1574, 977, 853 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.00 (s, 6H, CCH~3~, CCH~3~), 2.47--2.51 (m, 2H, COCH~2~), 2.83 (s, 2H, CCH~2~), 4.81--4.82 (m, 2H, CH~2~), 7.36--7.383 (m, 2H, ArH), 7.43--7.44 (m, 2H, ArH), 8.66 (s, 1H, CH), 9.44 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 28.2, 32.7, 44.2, 46.4, 51.1, 117.5, 127.8, 128.7, 128.7, 130.1, 132.0, 133.7, 155.8, 169.3, 195.1. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~18~H~19~ClN~3~O~3~, 360.1109, found, 360.1109.

### 2-((4-Fluorobenzyl)amino)-7,7-dimethyl-3-nitro-7,8-dihydroquinolin-5(6H)-one (**7g**) {#sec4.2.23}

Yellow solid; mp 124.0 °C; IR (KBr): 3379, 1683, 1591, 1502, 974, 852 cm^--1^; ^19^F NMR (470 MHz, DMSO-*d*~6~): δ −115.8; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.00 (s, 6H, CCH~3~, CCH~3~), 2.0 (s, 2H, COCH~2~), 2.85 (s, 2H, CCH~2~), 4.81--4.82 (m, 2H, CH~2~), 7.12--7.16 (m, 2H, ArH), 7.45--7.48 (m, 2H, ArH), 8.66 (s, 1H, CH), 9.42 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 28.2, 32.7, 44.1, 46.4, 51.1, 115.4 (d, *J* = 21.3 Hz), 117.5, 127.8, 130.3 (d, *J* = 8.8 Hz), 133.7, 135.5, 152.8, 161.7 (d, *J* = 241.3 Hz), 169.3, 195.1. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~18~H~19~FN~3~O~3~, 344.1405; found, 344.1404.

### 7,7-Dimethyl-3-nitro-2-(phenylamino)-7,8-dihydroquinolin-5(6H)-one (**7h**) {#sec4.2.24}

Yellow solid; mp 85 °C; IR (KBr): 3438, 1735, 16 311, 1461, 1190, 840 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.03 (s, 6H, CCH~3~, CCH~3~), 2.89 (s, 2H, COCH~2~), 3.35 (s, 2H, CCH~2~), 7.22 (s, 1H, ArH), 7.42 (s, 2H, ArH), 7.74 (s, 2H, ArH), 8.73 (s, 1H, CH), 10.32 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 28.2, 32.8, 46.2, 51.1, 119.0, 123.6, 125.5, 128.7, 129.2, 133.8, 138.1, 150.8, 168.9, 195.2. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~17~H~17~N~3~O~3~, 312.1343; found, 312.1338.

### 2-((4-Methoxyphenethyl)amino)-3-nitro-7,8-dihydroquinolin-5(6H)-one (**7i**) {#sec4.2.25}

Yellow solid; mp 129.0 °C; IR (KBr): 3365, 1672, 1603, 1512, 914, 809 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.02--2.07 (m, 2H, CH~2~), 2.55--2.58 (m, 2H, COCH~2~), 2.85--2.88 (m, 2H, ArCH~2~), 2.92--2.95 (m, 2H, CCH~2~), 3.72 (s, 2H, OCH~3~), 3.78--3.82 (m, 2H, NCH~2~), 6.85--6.87 (m, 2H, ArH), 7.17--7.19 (m, 2H, ArH), 8.63 (s, 1H, CH), 8.89 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.1, 33.1, 34.3, 37.8, 43.3, 37.8, 43.3, 55.5, 114.3, 118.2, 127.5, 130.1, 131.4, 134.1, 152.6, 158.3, 170.8, 195.1. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~18~H~20~N~3~O~4~, 342.1448; found, 342.1451.

### 2-((3-Methylphenethyl)amino)-3-nitro-7,8-dihydroquinolin-5(6H)-one (7j) {#sec4.2.26}

Yellow solid; mp 122.0 °C; IR (KBr): 3361, 1669, 1598, 1514, 954, 844 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.01--2.07 (m, 2H, CH~2~CH~2~CH~2~), 2.26 (S, 3H, CH~3~), 2.50 (S, 2H, COCH~2~), 2.87--2.90 (m, 2H, CH~2~), 2.94--2.96 (m, 2H, CCH~2~), 3.81--3.85 (m, 2H, NCH~2~), 7.10--7.16 (m, 4H, ArH), 8.65 (s, 1H, CH), 8.91 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ 21.0, 21.2, 33.2, 35.0, 37.9, 43.1, 118.7, 127.8, 128.6, 129.4, 135.1, 135.4, 136.3, 152.7, 170.3, 195.1. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~18~H~20~N~3~O~3~, 326.1499; found, 326.1501.

### 3-Nitro-2-(phenethylamino)-7,8-dihydroquinolin-5(6H)-one (**7k**) {#sec4.2.27}

Yellow solid; mp 130.0 °C; IR (KBr): 3374, 1671, 1598, 1572, 1134, 890 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.02--2.06 (m, 2H, CH~2~), 2.56--2.57 (m, 2H, COCH~2~), 2.93--2.94 (m, 4H, ArCH~2~, CCH~2~), 3.84--3.85 (m, 2H, NCH~2~), 7.21--7.22 (m, 1H, ArH), 7.27--7.32 (m, 4H, ArH), 8.63 (s, 1H, CH), 8.93 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.1, 33.1, 35.2, 37.8, 43.1, 118.2, 126.7, 127.6, 128.9, 129.2, 134.1, 139.6, 152.6, 170.8, 195.2. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~17~H~18~N~3~O~3~, 312.1343; found, 312.1342.

### 2-((3-Fluorophenethyl)amino)-3-nitro-7,8-dihydroquinolin-5 (6H)-one (**7l**) {#sec4.2.28}

Yellow solid; mp 149.0 °C; IR (KBr): 3376, 1677, 1603, 1587, 1045, 907 cm^--1^; ^19^F NMR (470 MHz, DMSO-*d*~6~): δ −113.6; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.02--2.07 (m, 2H, CH~2~), 2.56--2.58 (t, *J* = 6.5 Hz, 2H, COCH~2~), 2.93--2.98 (m, 4H, ArCH~2~, CCH~2~), 3.85--3.89 (m, 2H, NCH~2~), 7.09--7.13 (m, 2H, ArH), 7.31--7.36 (m, 1H, ArH), 8.64 (s, 1H, CH), 8.94 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.2, 33.1, 34.8, 37.8, 42.7, 113.5 (d, *J* = 20.0 Hz), 115.9 (d, *J* = 21.3 Hz), 118.3, 125.4 (d, *J* = 2.5 Hz), 127.6, 130.7 (d, *J* = 7.5 Hz), 134.1, 142.6 (d, *J* = 7.5 Hz), 152.6, 162.7 (d, *J* = 242.5 Hz), 170.8, 195.2. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~17~H~17~FN~3~O~3~ \[M + H\]+, 330.1248; found, 330.1241.

### 2-((2-Fluorophenethyl)amino)-3-nitro-7,8-dihydroquinolin-5 (6H)-one (**7m**) {#sec4.2.29}

Yellow solid; mp 146.0 °C; IR (KBr): 3373, 1672, 1600, 1087, 909 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ 2.11--2.17 (m, 2H, CH~2~), 2.62--2.64 (m, 2H, ArCH~2~), 2.96--2.98 (m, 2H, COCH~2~), 3.03--3.06 (m, 2H, CCH~2~), 3.94--3.98 (m, 2H, NCH~2~), 7.03--7.10 (m, 2H, ArH), 7.20--7.26 (m, 2H, ArH), 8.50 (s, 1H, CH), 8.98 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ 21.2, 29.1, 33.2, 38.0, 41.7, 115.5 (d, *J* = 22.5 Hz), 118.7, 124.3, 125.4 (d, *J* = 15.0 Hz), 127.8, 128.6 (d, *J* = 7.5 Hz), 131.1 (d, *J* = 3.8 Hz), 135.0, 152.9, 161.4 (d, *J* = 243.8 Hz), 170.3, 195.2. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~17~H~17~FN~3~O~3~, 330.1248; found, 330.1248.

### 2-((4-Chlorobenzyl)amino)-3-nitro-7,8-dihydroquinolin-5(6H)-one (**7n**) {#sec4.2.30}

Yellow solid; mp 109.1 °C; IR (KBr)3359, 1675, 1594, 1519, 954, 840 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.00--2.05 (m, 2H, CH~2~), 2.51--2.58 (m, 2H, COCH~2~), 2.88--2.91 (m, 2H, CCH~2~), 4.80--4.81 (m, 2H, NCH~2~), 7.36--7.37 (m, 2H, ArH), 7.42--7.44 (m, 2H, ArH), 8.66 (s, 1H, CH), 9.94 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.1, 33.0, 37.7, 44.2, 118.6, 127.9, 128.7, 130.1, 132.0, 134.1, 138.4, 152.4, 170.6, 195.1. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~16~H~15~ClN~3~O~3~, 332.0796; found, 332.0797.

### 2-((4-Methoxyphenethyl)amino)-3-nitro-5H-indeno\[1,2-*b*\]pyridin-5-one (**8a**) {#sec4.2.31}

Yellow solid; mp 192.5 °C; IR (KBr): 3367, 1705, 1617, 1595, 997, 825 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.93--2.96 (m, 2H, CH~2~), 3.69 (s, 3H, OCH~3~), 3.96--4.00 (m, 2H, NCH~2~), 6.86--6.88 (m, 2H, ArH), 7.24--7.25 (m, 2H, ArH), 7.67--7.70 (m, 1H, ArH), 7.75--7.81 (m, 2H, ArH), 7.91--7.92 (m, 1H, ArH), 8.47 (s, 1H, CH), 9.45 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ 34.7, 43.6, 55.3, 114.3, 117.5, 122.1, 123.8, 129.7, 130.3, 131.3, 132.8, 134.6, 138.3, 141.1, 156.0, 157.8, 158.6, 168.0, 170.0. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~21~H~18~N~3~O~4~, 376.1292; found, 376.1292.

### 2-((4-Methylphenethyl)amino)-3-nitro-5H-indeno\[1,2-*b*\]pyridin-5-one (**8b**) {#sec4.2.32}

Yellow solid; mp 197.0 °C; IR (KBr): 3356, 1708, 1616, 1585, 997, 767 cm^--1^; ^1^H NMR (600 MHz, CDCl~3~): δ 2.33 (s, 3H, CH~3~), 3.02--3.04 (m, 2H, CH~2~), 4.05--4.09 (m, 2H, NCH~2~), 7.15--7.20 (m, 3H, ArH), 7.24--7.28 (m, 1H, ArH), 7.55--7.58 (m, 1H, ArH), 7.64--7.66 (m, 1H, ArH), 7.76--7.77 (m, 1H, ArH), 7.87--7.88 (m, 1H, ArH), 8.66 (s, 1H, CH), 9.08 (br, 1H, NH); ^13^C NMR (150 MHz, CDCl~3~): δ 21.0, 35.1, 43.5, 117.5, 122.1, 123.8, 126.9, 128.6, 129.5, 131.2, 132.8, 134.6, 135.2, 136.5, 138.3, 141.1, 155.9, 170.0, 188.7. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~21~H~18~N~3~O~3~, 360.1343; found, 360.1343.

### 3-Nitro-2-(phenethylamino)-5H-indeno\[1,2-*b*\]pyridin-5-one (**8c**) {#sec4.2.33}

Yellow solid; mp 168.0 °C; IR (KBr): 3360, 1711, 1622, 1596, 1045, 803 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 3.00--3.02 (m, 2H, CH~2~), 3.96--4.00 (m, 2H, NCH~2~), 7.21--7.24 (m, 1H, ArH), 7.33--7.34 (m, 4H, ArH), 7.64--7.67 (m, 1H, ArH), 7.71--7.72 (m, 1H, ArH), 7.74--7.78 (m, 1H, ArH), 7.85--7.86 (m, 1H, ArH), 8.40 (s, 1H, CH), 8.51 (s, 1H, CH), 9.44 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 35.4, 43.6, 116.7, 122.3, 123.8, 126.8, 126.8, 129.0, 129.2, 131.0, 133.6, 135.6, 138.0, 139.4, 140.8, 155.6, 169.5, 188.3. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~20~H~16~N~3~O~3~, 346.1186; found, 346.1186.

### 2-((3-Fluorophenethyl)amino)-3-nitro-5H-indeno\[1,2-*b*\]pyridin-5-one (**8d**) {#sec4.2.34}

Yellow solid; mp 183.5 °C; IR (KBr): 3337, 1703, 1616, 1583, 997, 936 cm^--1^; ^19^F NMR (470 MHz, DMSO-*d*~6~): δ −113.3; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 3.06--3.09 (m, 2H, CH~2~), 4.06--4.10 (m, 2H, NCH~2~), 6.93--6.96 (m, 1H, ArH), 7.08--7.13 (m, 2H, ArH), 7.30--7.34 (m, 1H, ArH), 7.61--7.64 (m, 1H, ArH), 7.71--7.74 (m, 2H, ArH), 8.04 (s, 1H, ArH), 8.51 (s, 1H, CH), 9.37 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 35.4, 43.0, 113.8 (d, *J* = 21.3 Hz), 115.6 (d, *J* = 20.0 Hz), 117.6, 122.1, 123.8, 124.4, 127.0, 130.3 (d, *J* = 8.8 Hz), 131.2, 132.9, 134.7, 138.2, 140.9 (d, *J* = 23.8 Hz), 115.9, 162.1, 164.1, 170.0, 188.6. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~20~H~15~FN~3~O~3~, 364.1092; found, 364.1094.

### 2-((2-Fluorophenethyl)amino)-3-nitro-5H-indeno\[1,2-*b*\]pyridin-5-one (**8e**) {#sec4.2.35}

Yellow solid; mp 195.0 °C; IR (KBr): 3338, 1704, 1617, 1586, 956, 904 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 3.05--3.08 (m, 2H, CH~2~), 4.00--4.04 (m, 2H, NCH~2~), 7.11--7.14 (m, 2H, ArH), 7.15--7.25 (m, 1H, ArH), 7.35--7.38 (m, 1H, ArH), 7.65--7.66 (m, 1H, ArH), 7.68--7.69 (m, 1H, ArH), 7.78--7.80 (m, 1H, ArH), 7.81--7.87 (m, 1H, ArH), 8.44 (s, 1H, CH), 9.53 (br, 1H, NH); ^13^C NMR (150 MHz, CDCl~3~): δ 29.4, 42.0, 115.5, 115.6, 117.6, 122.1, 123.8, 124.4, 125.3 (d, *J* = 16.5 Hz), 126.9, 128.7 (d, *J* = 7.5 Hz), 131.2 (d, *J* = 6.0 Hz), 132.8, 134.6, 138.2, 141.1, 156.0, 162.3, 169.9, 188.7. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~20~H~15~FN~3~O~3~, 364.1092; found, 364.1094.

### 2-((4-Chlorobenzyl)amino)-3-nitro-5H-indeno\[1, 2-*b*\]pyridin-5-one (**8f**) {#sec4.2.36}

Yellow solid; mp 228.0 °C; IR (KBr): 3368, 1735, 1654, 1618, 942, 836 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 4.94--4.96 (m, 2H, CH~2~), 7.38--7.40 (m, 2H, ArH), 7.54--7.55 (m, 2H, ArH), 7.66--7.68 (m, 1H, ArH), 7.73--7.78 (m, 2H, ArH), 7.86--7.88 (m, 1H, ArH), 8.47 (s, 1H, CH), 8.94 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ 45.1, 118.1, 122.1, 123.9, 127.2, 129.1, 129.2, 131.3, 132.9, 133.8, 134.8, 135.9, 138.2, 141.0, 155.7, 170.0, 188.5. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~19~H~13~ClN~3~O~3~, 366.0640; found, 5366.0641.

### 3-Nitro-2-(phenylamino)-5H-indeno\[1,2-*b*\]pyridin-5-one (**8g**) {#sec4.2.37}

Yellow solid; mp 176.6 °C; IR (KBr): 3378, 1730, 1604, 1530, 1285.36, 1130.35 cm^--1^; ^1^H NMR (600 MHz, CDCl~3~): δ 7.26--7.29 (m, 1H, ArH), 7.45--7.48 (m, 2H, ArH), 7.55--7.58 (m, 1H, ArH), 7.62--7.64 (m, 1H, ArH), 7.76--7.81 (m, 1H, ArH), 8.74 (s, 1H, CH), 10.89 (br, 1H, NH); ^13^C NMR (150 MHz, CDCl~3~): δ 119.2, 122.4, 122.9, 123.9, 125.8, 127.3, 129.1, 131.4, 133.0, 134.8, 137.1, 138.0, 140.9, 153.5, 169.8, 188.4. HRMS (TOF ES^+^) *m*/*z*: \[M + H\]^+^ calcd for C~18~H~12~N~3~O~3~, 318.0873; found, 318.0873.

### 2-(Methylamino)-3-nitro-5H-indeno\[1,2-*b*\]pyridin-5-one (**8h**) {#sec4.2.38}

Yellow solid; mp 121.8 °C; IR (KBr): 3378, 1730, 1604, 1530, 1285, 1130 cm^--1^; ^1^H NMR (600 MHz, DMSO): δ 3.25--3.28 (d, 3H, CH~3~), 7.66--7.68 (m, 1H, ArH), 7.73--7.77 (m, 2H, ArH), 7.87--7.88 (m, 1H, ArH), 8.44 (s, 1H, CH), 9.41 (br, 1H, NH); ^13^C NMR (150 MHz, DMSO): δ 29.5, 116.4, 122.4, 123.8, 127.2, 130.9, 133.6, 135.6, 138.1, 140.9, 156.1, 169.6, 188.5. HRMS (TOF ES^+^) *m*/*z*: calcd for C~13~H~10~N~3~O~3~, 256.0717; found, 256.0717.
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